Emi Yokoyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emi Yokoyama has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Shin Morizane
Department of Dermatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
6 shared publications - Yoshio Kawakami
Department of Dermatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
4 shared publications - Osamu Yamasaki
Department of Dermatology, Shimane University Faculty of Medicine
3 shared publications Shin Morizane
3 shared publications- Yoji Hirai
Department of Dermatology Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
3 shared publications Ai Kajita
Department of Dermatology Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
2 shared publications
Latest Publications
- 1 October 2024
- Published by JLE in European Journal Of Dermatology
- Vol. 34 (5) , 539-541
A case of anaphylaxis to kumquat (Citrus japonica)
- 1 October 2024
- Published by JLE in European Journal Of Dermatology
- Vol. 34 (5) , 539-541
A case of anaphylaxis to kumquat (Citrus japonica)
- Open Access
- 1 July 2024
- Published by Medknow in Indian Journal of Dermatology
- Vol. 69 (4) , 350-352
A Gardner-Diamond Syndrome Accompanied by Complex Regional Pain Syndrome
- 1 July 2024
- Published by Medknow in Indian Journal of Dermatology
- Vol. 69 (4) , 350-352
Open AccessA Gardner-Diamond Syndrome Accompanied by Complex Regional Pain Syndrome
- 10 November 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (4) , e125-e126
Pruritic folliculitis of pregnancy with granular deposition of immunoglobulin G along the basement membrane zone
- 10 November 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (4) , e125-e126
Pruritic folliculitis of pregnancy with granular deposition of immunoglobulin G along the basement membrane zone
- 14 August 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (12) , e413-e414
Successful treatment with secukinumab in a patient with generalized pustular psoriasis preceded by palmoplantar lesions
- 14 August 2023
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (12) , e413-e414
Successful treatment with secukinumab in a patient with generalized pustular psoriasis preceded by palmoplantar lesions
- 22 October 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (4) , E214-E215
A case of neuro‐Behcet's disease preceded by cellulitis‐like cutaneous arteritis and multiple pharyngeal ulcers
- 22 October 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (4) , E214-E215
A case of neuro‐Behcet's disease preceded by cellulitis‐like cutaneous arteritis and multiple pharyngeal ulcers
- 1 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (4) , E149-E150
Impetigo herpetiformis successfully treated with brodalumab
- 1 April 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (4) , E149-E150
Impetigo herpetiformis successfully treated with brodalumab
- 1 January 2022
- Vol. 63 (1) , 51-54
[Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
The patient was a 68-year-old woman, diagnosed with acute myelomonocytic leukemia with normal karyotype and FLT3-ITD-negative status in May 2019. She had achieved complete remission (CR) after "7+3" intensive induction chemotherapy and maintained CR by consolidation chemotherapy. However, she relapsed with swelling of the lips and gums in January 2020. She did not achieve CR by salvage chemotherapy with cytarabine-aclarubicin-G-CSF regimen. Comprehensive genomic analysis of leukemic cells revealed the presence of FLT3-N676K mutation, which was undetectable by companion diagnostics at the time. Complete remission with incomplete count recovery was obtained on day 28 after initiation of gilteritinib monotherapy, and the lip and gum swelling improved rapidly. However, she relapsed on day 106 after gilteritinib administration, and gilteritinib was discontinued. Genomic analysis at recurrence revealed NRAS mutation for the first time. Finally, the patient died of the uncontrolled primary disease. This is a case in which comprehensive gene mutation analysis was useful in determining a treatment strategy.
- 1 January 2022
- Vol. 63 (1) , 51-54
[Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
The patient was a 68-year-old woman, diagnosed with acute myelomonocytic leukemia with normal karyotype and FLT3-ITD-negative status in May 2019. She had achieved complete remission (CR) after "7+3" intensive induction chemotherapy and maintained CR by consolidation chemotherapy. However, she relapsed with swelling of the lips and gums in January 2020. She did not achieve CR by salvage chemotherapy with cytarabine-aclarubicin-G-CSF regimen. Comprehensive genomic analysis of leukemic cells revealed the presence of FLT3-N676K mutation, which was undetectable by companion diagnostics at the time. Complete remission with incomplete count recovery was obtained on day 28 after initiation of gilteritinib monotherapy, and the lip and gum swelling improved rapidly. However, she relapsed on day 106 after gilteritinib administration, and gilteritinib was discontinued. Genomic analysis at recurrence revealed NRAS mutation for the first time. Finally, the patient died of the uncontrolled primary disease. This is a case in which comprehensive gene mutation analysis was useful in determining a treatment strategy.
- Open Access
- 13 December 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (3) , 1761-1767
Multiple Colorectal Mucosa-Associated Lymphoid Tissue Lymphoma Successfully Treated with Chemotherapy
The standard treatment for colorectal mucosa-associated lymphoid tissue (MALT) lymphoma has not yet been established due to the rarity of the disease. Here, we report a case of long-term response to chemotherapy for colorectal MALT lymphoma (stage I). A 77-year-old frail female patient with diabetes mellitus and dementia developed melena of unknown etiology, and a colonoscopy was performed at a nearby hospital. A biopsy suggested malignant lymphoma, and she was referred to our department. As a result of re-examination of colonoscopy, a total of 3 submucosal tumor-like lesions were confirmed. Of these, a biopsy of the lesions in the ascending colon and rectum was performed, and MALT lymphoma was diagnosed on the basis of the histopathological findings. Following close examination, no other lymphoma lesions were found, and the patient was diagnosed with primary colorectal MALT lymphoma, stage I. After 1 course of R-THP-COP chemotherapy (rituximab + cyclophosphamide, pirarubicin, vincristine, and prednisone), the rectal lesion was confirmed to have almost disappeared endoscopically, and lymphoma cells were not found histopathologically. The patient was determined to be in complete remission (CR). However, due to hematological toxicity and a slight worsening of glucose control, the second chemotherapy course was changed to the BR regimen (rituximab + bendamustine), and 4 courses were performed (5 total courses of chemotherapy). Currently, >3 years have passed since reaching CR, and the patient is alive without recurrence.
- 13 December 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (3) , 1761-1767
Open AccessMultiple Colorectal Mucosa-Associated Lymphoid Tissue Lymphoma Successfully Treated with Chemotherapy
The standard treatment for colorectal mucosa-associated lymphoid tissue (MALT) lymphoma has not yet been established due to the rarity of the disease. Here, we report a case of long-term response to chemotherapy for colorectal MALT lymphoma (stage I). A 77-year-old frail female patient with diabetes mellitus and dementia developed melena of unknown etiology, and a colonoscopy was performed at a nearby hospital. A biopsy suggested malignant lymphoma, and she was referred to our department. As a result of re-examination of colonoscopy, a total of 3 submucosal tumor-like lesions were confirmed. Of these, a biopsy of the lesions in the ascending colon and rectum was performed, and MALT lymphoma was diagnosed on the basis of the histopathological findings. Following close examination, no other lymphoma lesions were found, and the patient was diagnosed with primary colorectal MALT lymphoma, stage I. After 1 course of R-THP-COP chemotherapy (rituximab + cyclophosphamide, pirarubicin, vincristine, and prednisone), the rectal lesion was confirmed to have almost disappeared endoscopically, and lymphoma cells were not found histopathologically. The patient was determined to be in complete remission (CR). However, due to hematological toxicity and a slight worsening of glucose control, the second chemotherapy course was changed to the BR regimen (rituximab + bendamustine), and 4 courses were performed (5 total courses of chemotherapy). Currently, >3 years have passed since reaching CR, and the patient is alive without recurrence.
- Open Access
- 1 December 2021
- Published by Frontiers Media SA in Journal of Cutaneous Immunology and Allergy
- Vol. 4 (6) , 170-172
A case of bullous pemphigoid after a long-term administration of anti-PD-1 antibodies in a patient with non-small-cell lung cancer
We described a case of BP that developed 2.5 years after the administration of nivolumab for metastatic non-small cell lung cancer. Our report highlights the fact that dermatologists should be aware of anti PD-1-related BP, which can appear very late during treatment.
- 1 December 2021
- Published by Frontiers Media SA in Journal of Cutaneous Immunology and Allergy
- Vol. 4 (6) , 170-172
Open AccessA case of bullous pemphigoid after a long-term administration of anti-PD-1 antibodies in a patient with non-small-cell lung cancer
We described a case of BP that developed 2.5 years after the administration of nivolumab for metastatic non-small cell lung cancer. Our report highlights the fact that dermatologists should be aware of anti PD-1-related BP, which can appear very late during treatment.
- 7 October 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (1) , E9-E10
Persistent local inflammation surrounding cement substance of a tick Amblyomma testudinarium after sufficient removal of its mouthpart
- 7 October 2021
- Published by Wiley in The Journal of Dermatology
- Vol. 49 (1) , E9-E10
Persistent local inflammation surrounding cement substance of a tick Amblyomma testudinarium after sufficient removal of its mouthpart